Profound Medical (NASDAQ:PROF – Get Free Report) and INVO Bioscience (NASDAQ:INVO – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.
Insider & Institutional Ownership
47.9% of Profound Medical shares are held by institutional investors. Comparatively, 12.0% of INVO Bioscience shares are held by institutional investors. 1.5% of Profound Medical shares are held by company insiders. Comparatively, 3.5% of INVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk and Volatility
Profound Medical has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, INVO Bioscience has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500.
Earnings & Valuation
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Profound Medical | $10.68 million | 19.55 | -$28.57 million | ($1.12) | -6.21 |
INVO Bioscience | $5.77 million | 0.14 | -$8.03 million | N/A | N/A |
INVO Bioscience has lower revenue, but higher earnings than Profound Medical.
Analyst Ratings
This is a breakdown of recent ratings for Profound Medical and INVO Bioscience, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Profound Medical | 0 | 0 | 2 | 1 | 3.33 |
INVO Bioscience | 0 | 0 | 0 | 0 | 0.00 |
Profound Medical presently has a consensus price target of $14.25, suggesting a potential upside of 105.04%. Given Profound Medical’s stronger consensus rating and higher possible upside, research analysts clearly believe Profound Medical is more favorable than INVO Bioscience.
Profitability
This table compares Profound Medical and INVO Bioscience’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Profound Medical | -349.41% | -85.22% | -64.87% |
INVO Bioscience | -122.79% | N/A | -36.94% |
Summary
Profound Medical beats INVO Bioscience on 7 of the 13 factors compared between the two stocks.
About Profound Medical
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
About INVO Bioscience
INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.
Receive News & Ratings for Profound Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medical and related companies with MarketBeat.com's FREE daily email newsletter.